Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
5.93
-0.04 (-0.67%)
Mar 20, 2026, 1:35 PM CST
Market Cap6.13B -16.5%
Revenue (ttm)578.61M -26.0%
Net Income83.77M +1.7%
EPS0.08 -2.5%
Shares Out1.03B
PE Ratio75.46
Forward PEn/a
Dividend0.02 (0.33%)
Ex-Dividend DateJul 4, 2025
Volume12,706,100
Average Volume15,086,083
Open6.12
Previous Close5.97
Day's Range5.87 - 6.12
52-Week Range5.87 - 8.74
Beta0.31
RSI29.01
Earnings DateApr 23, 2026

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People’s Republic of China and internationally. The company’s finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibroblast growth factor gel; human interleukin-11; arsen... [Read more]

Sector Healthcare
Founded 1994
Employees 889
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

Financial Statements